This post is presented by our media partner Psychedelic News Wire
View the original article here.
Psychedelics have captured the scientific and mental-health communities’ attention due to extensive claims of their medical efficacy, particularly against hard-to-treat mental disorders. Several studies have connected psychedelics such as psilocybin (magic mushrooms), LSD and MDMA with significant and long-term improvements in mental health.
These studies have found that psychedelic therapy can be especially effective when it is paired with traditional psychotherapy and often induces profound and long-term benefits at small doses and with relatively few side effects. Even though the psychedelic field is still in the early research phase, results from clinical studies as well as anecdotal accounts have been so encouraging that an increasing number of Americans are choosing to microdose various psychedelics for health and wellness reasons.
People as diverse as everyday moms to high-level executives have dabbled in microdosing psychedelics in recent years. Many of them report improvements in creativity, focus and mental health as a result. Some folks are even using psychedelics to supplement their ADHD treatment in a move that could revolutionize how physicians perceive and treat attention-deficit hyperactivity disorder.
Studies indicate that taking small doses of hallucinogenic substances may alleviate some of the symptoms that affect people with ADHD and improve their mindfulness. These improvements seem to remain even when ADHD patients microdose psychedelics alongside conventional treatments, opening the door to new treatment protocols that leverage both psychedelics and pharmaceutical medications.
Pharmaceuticals such as Concerta, Ritalin and Adderall are often used to reduce hyperactivity and impulsivity in patients with ADHD. However, they rarely help adults with the condition deal with the challenges involved in living with ADHD, such as struggling to be present in the moment or dealing with emotional instability. In fact, some medications can even exacerbate symptoms such as stress and anxiety, which makes the day-to-day lives of adults with ADHD even more challenging.
Stacking psychedelics microdosing with prescription ADHD medications could allow patients to treat the classic impulsivity, hyperactivity and inability to focus associated with ADHD and alleviate poor mental-health symptoms. This could result in more comprehensive treatment protocols that would treat a much wider profile of symptoms and offer patients greater relief across the board.
A recent microdosing study that was published in the “Frontiers in Psychiatry Journal” found that psychedelic microdosers who had ADHD exhibited more levels of mindfulness and lower levels of emotional instability compared to the general population. The study also found that pharmaceutical ADHD medications did not affect psychedelics’ ability to improve mental health when stacked, indicating that both approaches offer separate therapeutic pathways. This could result in the development of personalized treatment protocols that use both pharmaceuticals and psychedelics to treat the full breadth of ADHD symptoms with no additional side effects.
With entities such as Seelos Therapeutics Inc. (NASDAQ: SEEL) studying the potential applications of psychedelics in treating a host of other mental -health conditions, the full extent of the medicinal value of these substances may yet expand beyond what is currently known.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
